Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
Vistagen (Nasdaq: VTGN) appointed Nick Tressler as Chief Financial Officer effective December 1, 2025. Mr. Tressler has over 20 years of life‑science financial leadership, most recently serving as CFO of DYNEX Technologies and previously at American Gene Technologies and Senseonics (Nasdaq: SENS). He held senior roles at Sucampo (acquired 2018) and MedImmune (acquired 2007) and holds an MBA from Johns Hopkins.
The Compensation Committee granted an inducement incentive option for 150,000 shares with an exercise price equal to the December 1, 2025 closing price; vesting is 25% after one year, then monthly ratable vesting over 36 months.
Vistagen (Nasdaq: VTGN) presented exploratory data at The Menopause Society 2025 Annual Meeting showing that intranasal PH80 produced rapid-onset effects on autonomic biomarkers of vasomotor symptoms without systemic absorption. The company reported PH80 was not detected in human blood, did not bind steroid hormone or neurotransmitter receptors, and dose-dependently depolarized nasal receptor electrograms (EGNR).
These studies, conducted 1995–2000 and sponsored by Pherin Pharmaceuticals (now a Vistagen subsidiary), support a proposed non-hormonal, non-systemic, rapidly acting mechanism for treating menopausal hot flashes; posters are available on the company publications page.
Vistagen (Nasdaq: VTGN) reported fiscal 2026 second quarter results and a program update on November 13, 2025. PALISADE-3 randomized, double-blinded portion is complete and topline results are expected in Q4 2025. A duplicate trial, PALISADE-4, has topline randomized results expected in the first half of 2026. For the three months ended September 30, 2025, R&D expense was $15.9 million (prior-year $10.2M), G&A expense $4.4 million (prior-year $4.2M), and net loss was $19.4 million (prior-year $13.0M). Cash, cash equivalents, and marketable securities were $77.2 million as of September 30, 2025. The company also announced a board appointment and is hosting a conference call on November 13, 2025 at 5:00 p.m. ET.
Vistagen (Nasdaq: VTGN) will report fiscal year 2026 second quarter results for the period ended September 30, 2025 and host a corporate update conference call on Thursday, November 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET. The event will be webcast live via the Investors > Events section of the company website; registration is recommended at least 10 minutes before the call. The webcast will be archived on the company website and available for at least 90 days. Dial-in details: Conference ID 6458570, Toll-Free 1(646) 307-1952, International 1(646) 307-1963.
Vistagen (Nasdaq: VTGN) announced that President and CEO Shawn Singh will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 12, 2025 from 3:20–3:50 p.m. ET.
The company will host one-on-one meetings during the conference and a live webcast will be available via the Events page in the Investors section at www.Vistagen.com. A replay of the webcast will be archived and available after the event.
Vistagen (Nasdaq: VTGN) announced completion of the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 public speaking challenge study for the acute treatment of social anxiety disorder. The company said topline results are expected by year-end 2025 and an open-label extension is ongoing where participants may use fasedienol for up to 12 months.
Vistagen noted PALISADE-3 uses the same design and primary endpoint as the previously positive PALISADE-2 trial, and that PALISADE-4 topline results are anticipated in first half of 2026. The FDA has granted Fast Track designation for fasedienol for acute social anxiety disorder.
Vistagen (Nasdaq: VTGN) announced the appointment of Paul Edick to its Board of Directors effective October 29, 2025. Following the appointment the Board will have seven directors.
Mr. Edick will serve on the Audit Committee and the Compensation Committee. He most recently served as Chairman and CEO of Xeris Pharmaceuticals from January 2017 to August 2024 and moved to a senior advisory role after retiring. His prior roles include CEO of Durata Therapeutics (acquired by Actavis) and founding partner of 3G Advisors. Vistagen thanked Dr. Jerry Gin, who served on the Board from 2016 until his retirement in September 2025.
Vistagen (NASDAQ: VTGN) will present poster data on its investigational intranasal pherine PH80 at The Menopause Society 2025 Annual Meeting in Orlando on October 23, 2025. The posters report nonclinical and Phase 1 clinical results exploring PH80’s in vitro receptor binding, effects on reproductive organs in mice, human pharmacokinetics, and impacts on brain and autonomic activity.
PH80 is described as a novel, non-hormonal, non-systemic, rapidly acting pherine nasal spray being evaluated as a potential treatment for vasomotor symptoms (hot flashes) due to menopause. Poster sessions are scheduled for 6:15–7:15 p.m. ET (Poster P-124 and P-13).
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and pherine-based intranasal treatments, announced its participation in the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. CEO Shawn Singh will engage in a fireside chat on September 18, 2025, at 2:20 p.m. ET.
The presentation will be available via live webcast on Vistagen's investor relations website, with a replay option available afterward. The company will also conduct one-on-one meetings during the conference.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company, reported its fiscal Q1 2026 financial results and provided updates on its pherine pipeline. The company's lead program, fasedienol for social anxiety disorder (SAD), is advancing with PALISADE-3 Phase 3 trial results expected in Q4 2025 and PALISADE-4 results in H1 2026.
Financial highlights include R&D expenses of $11.7M (up from $7.6M YoY), G&A expenses of $4.4M, and a net loss of $15.1M. The company maintains a strong cash position of $63.2M as of June 30, 2025.
Vistagen is developing multiple clinical-stage intranasal pherine candidates, including PH80 for menopausal hot flashes and itruvone for major depressive disorder (MDD). The company recently appointed Elissa Cote as Chief Corporate Development Officer.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
